Rabium 20 mg (Tablet (Enteric Coated))
Unit Price: ৳ 5.00 (50's pack: ৳ 250.00)
Medicine Details
Category | Details |
---|---|
Generic | Rabeprazole sodium |
Company | Cosmic pharma ltd |
Title
- Rabium Gastro-resistant Tablets
Categories
- Medicine
- Gastrointestinal
Description
- Proton pump inhibitor for the treatment of active duodenal ulcer, active benign gastric ulcer, GERD, and Zollinger-Ellison Syndrome, in pediatric and adult patients
Indication
- Active duodenal ulcer
- Active benign gastric ulcer
- Symptomatic erosive or ulcerative gastro-esophageal reflux disease (GERD)
- Gastro-esophageal Reflux Disease Long-term Management (GERD Maintenance)
- Symptomatic treatment of moderate to very severe gastro-esophageal reflux disease (symptomatic GERD)
- Zollinger-Ellison Syndrome
- In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori in patients with peptic ulcer disease
Pharmacology
- Suppresses gastric acid secretion by inhibiting the gastric H+/K+-ATPase
Dosage
- 20 mg once daily for active duodenal ulcer and active benign gastric ulcer
- 20 mg once daily for 4-8 weeks for erosive or ulcerative GERD
- 20 mg or 10 mg once daily for long-term management of GERD
- 10 mg once daily for symptomatic GERD treatment
- 5 mg or 10 mg once daily for pediatric GERD patients
- Starting dose of 60 mg once daily for Zollinger-Ellison Syndrome, titrated upwards based on individual needs
- Combination therapy for H. pylori eradication
Administration
- To be taken in the morning before eating, should be swallowed whole
Interaction
- Potential interaction with compounds dependent on pH for absorption
- Co-administration with ketoconazole or itraconazole may decrease antifungal plasma levels
- No interaction with liquid antacids observed
- Atazanavir absorption is pH-dependent, should not be co-administered with PPIs
Contraindications
- Hypersensitivity to the active substance or excipients
- Contra-indicated in pregnancy and during breastfeeding
Side effects
- Well-tolerated, may cause headache, diarrhea, abdominal pain, vomiting, constipation, dry mouth, changes in appetite, muscle pain, drowsiness, dizziness
Pregnancy and lactation
- US FDA pregnancy category 'C'
- No adequate and well-controlled studies in pregnant women
- Likely excreted in human milk, decision should consider risks and benefits to the mother
Precautions and warnings
- Possibility of gastric or esophageal malignancy should be excluded prior to treatment
- Regular surveillance for long-term treatment
- Modestly increase risk of hip, wrist, spine fracture especially in the elderly or with other risk factors
- Cross-hypersensitivity reactions possible with other PPIs
- Hepatic enzyme abnormalities and drug related safety problems reported
- Severe hypomagnesaemia reported after prolonged PPI treatment
- Reduction in vitamin B12 absorption, risk of subacute cutaneous lupus erythematosus
- Reduced absorption of vitamin D and interference with laboratory tests
Special populations
- No dosage adjustment for renal or hepatic impairment
- Not recommended for use in children
Overdose effects
- Effects generally minimal and reversible without medical intervention
- No specific antidote known, not dialysable
- Treatment should be symptomatic and supportive
Chemical structure
- Molecular Formula: C18H21N3O3S
Commonly asked questions
- Description of the tablet
- Recommended uses
- Common side effects
- Dosage and administration guidelines
- Recommendations for pregnant or breastfeeding individuals
- Actions in case of overdose
- Duration of treatment
- Other considerations and precautions
Storage conditions
- Keep below 30°C, away from light and moisture
- Keep out of the reach of children
Therapeutic class
- Proton Pump Inhibitor